It was estimated that 80% (95% CI 65–92) of the patients that were infected with SARS-CoV-2 developed one or more long-term symptoms. The age of the study participants ranged between 17 and 87 years. The follow-up time ranged from 14 to 110 days post-viral infection. The prevalence of 55 long-term effects was estimated, 21 meta-analyses were performed, and 47,910 patients were included. A total of 18,251 publications were identified, of which 15 met the inclusion criteria. This systematic review followed Preferred Reporting Items for Systematic Reviewers and Meta-analysis (PRISMA) guidelines, although the study protocol was not registered. Heterogeneity was assessed using I 2 statistics. For effects reported in two or more studies, meta-analyses using a random-effects model were performed using the MetaXL software to estimate the pooled prevalence with 95% CI. All articles with original data for detecting long-term COVID-19 published before 1 st of January 2021 and with a minimum of 100 patients were included. LitCOVID (PubMed and Medline) and Embase were searched by two independent researchers. This systematic review and meta-analysis aims to identify studies assessing long-term effects of COVID-19 and estimates the prevalence of each symptom, sign, or laboratory parameter of patients at a post-COVID-19 stage. COVID-19, caused by SARS-CoV-2, can involve sequelae and other medical complications that last weeks to months after initial recovery, which has come to be called Long-COVID or COVID long-haulers.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |